Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun;5(2):83-7.
doi: 10.1007/s13539-014-0149-7. Epub 2014 May 28.

Are we closer to having drugs to treat muscle wasting disease?

John E Morley  1 , Stephan von Haehling, Stefan D Anker
Affiliations

Are we closer to having drugs to treat muscle wasting disease?

John E Morley et al. J Cachexia Sarcopenia Muscle. 2014 Jun.

Abstract

The two most common muscle wasting diseases in adults are sarcopenia and cachexia. Despite differences in their pathophysiology, it is believed that both conditions are likely to respond to drugs that increase muscle mass and muscle strength. The current gold standard in this regard is exercise training. This article provides an overview of candidate drugs to treat muscle wasting disease that are available or in development. Drugs highlighted here include ghrelin agonists, selective androgen receptor molecules, megestrol acetate, activin receptor antagonists, espindolol, and fast skeletal muscle troponin inhibitors.

PubMed Disclaimer

References

    1. Farkas J, von Haehling S, Kalantar-Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle. 2013;4:173–8. doi: 10.1007/s13539-013-0105-y. - DOI - PMC - PubMed
    1. von Haehling S, Morley JE, Anker SD. From muscle wasting to sarcopenia and myopenia: update 2012. J Cachexia Sarcopenia Muscle. 2012;3:213–7. doi: 10.1007/s13539-012-0089-z. - DOI - PMC - PubMed
    1. Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, et al. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14:392–7. doi: 10.1016/j.jamda.2013.03.022. - DOI - PMC - PubMed
    1. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: european consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39:412–23. doi: 10.1093/ageing/afq034. - DOI - PMC - PubMed
    1. Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, et al. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc. 2011;12:403–9. doi: 10.1016/j.jamda.2011.04.014. - DOI - PMC - PubMed